Sagimet Biosciences Reports Q2 2026 Financial Results

What Happened

• On August 11, 2026, Sagimet Biosciences, Inc. announced its financial results for the quarter ended June 30, 2026. The company furnished a press release and an updated investor slide presentation as exhibits to a Current Report on Form 8‑K.
• The press release is attached as Exhibit 99.1 and the updated investor presentation is attached as Exhibit 99.2 (both dated August 11, 2026). The filing also includes the Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.
• The company notes the investor presentation is being used in meetings with investors and the update is disclosed under Regulation FD (Item 7.01). The exhibits were furnished (not filed) with the SEC.

Key Details

• Announcement date: August 11, 2026.
• Quarter covered: quarter ended June 30, 2026 (quarterly results / earnings announcement).
• Exhibits furnished: 99.1 (press release), 99.2 (investor presentation), 104 (Inline XBRL cover page).
• SEC items referenced: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

Why It Matters

• The 8‑K signals that Sagimet has released its latest quarterly results and updated investor materials—investors should read the press release and slide deck for specific earnings, revenue, cash position, and any management commentary or outlook.
• Because the presentation was updated and will be used in investor meetings (Regulation FD disclosure), the information is public and could influence market reaction as analysts and investors absorb the quarterly results and any guidance.
• Action for investors: review Exhibits 99.1 and 99.2 on the SEC EDGAR site or Sagimet’s investor page to see the full financial details and any changes to outlook or strategy.